Patent · US Active

Compounds for targeting cancer stem cells

US11427543B2 · kind B2 · utility

0Cited by
2References
9Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJul 18, 2017
Grant dateAug 30, 2022
Priority date
Expiry dateOct 11, 2039

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D213/53
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

This invention relates to antagonists of G3BP2, G3BP1, and ZEB1. Pharmaceutical compositions comprising G3BP2 inhibitors, methods of inhibiting G3BP2, G3BP1, and ZEB1, methods of treating cancer and inflammation, and methods of identifying an inhibitor of cancer stems cells are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.